EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and emerging drugs for Parkinson’s disease: mechanisms, clinical evidence, and future directions

Fang Yang

Frontiers in Pharmacology · 29.06.2026 · 17

DOI: 10.3389/fphar.2026.1805370 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Fang Yang. Beteiligte Einrichtung: Department of Neurology, Xinchang County People's Hospital, Shaoxing, Zhejiang, China. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein pathology, resulting in disabling motor and non-motor symptoms. Pharmacotherapy remains the cornerstone of PD management, yet current treatments are largely symptomatic and fail to halt disease progression. In recent years, substantial advances have been made in both dopaminergic and non-dopaminergic therapeutic strategies. Novel formulations of levodopa and dopamine agonists aim to provide more stable dopaminergic stimulation and reduce motor fluctuations. Meanwhile, emerging non-dopaminergic agents targeting glutamatergic, serotonergic, adenosinergic, and cholinergic systems offer new options for managing dyskinesia, gait impairment, and neuropsychiatric symptoms. Importantly, growing efforts are directed toward disease-modifying therapies, including α-synuclein immunotherapy, inhibitors of protein misfolding and aggregation, glucocerebrosidase-targeted interventions, and neuroprotective agents that modulate mitochondrial dysfunction, oxidative stress, inflammation, and metabolic signaling. Although many candidates have shown encouraging preclinical or early clinical results, definitive disease-modifying efficacy remains to be established. This review summarizes recent progress in PD pharmacotherapy, highlights translational challenges, and discusses future directions toward precision medicine and combination strategies for achieving sustained symptomatic control and disease modification.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseaseclinical translationdisease-modifying therapydopaminergic therapyneuroprotectionα-synuclein

Autor:innen und Institutionen

  • Department of Neurology, Xinchang County People's Hospital, Shaoxing, Zhejiang, China.

Zitieren

APA

Yang, F. (2026). Current and emerging drugs for Parkinson’s disease: mechanisms, clinical evidence, and future directions. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1805370

Vancouver

Yang F. Current and emerging drugs for Parkinson’s disease: mechanisms, clinical evidence, and future directions. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1805370

BibTeX
@article{Yang2026,
  author = {Yang, Fang},
  title = {Current and emerging drugs for Parkinson’s disease: mechanisms, clinical evidence, and future directions},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1805370}
}
Kostenlos starten →